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Introduction
Genetic immunization using naked plasmid DNA is attract-
ing increasing interest in tumor immunology since DNA vac-
cines combine many desirable attributes, particularly under the 
aspect of clinical applicability. DNA vaccines (1) code for mul-
tiple MHC Class I- and Class II-restricted epitopes that may be 
presented to both CD4+ and CD8+ T cells; (2) lead to a prefer-
ential MHC Class I expression of the antigen; (3) can induce 
both T-cell and humoral responses; (4) can contain CpG-rich 
sequences that are highly immunogenic; (5) can be produced at 
comparably low costs as a “general” vaccine being applicable to 
most individuals across HLA barriers; and (6) are considered far 
safer than viral vectors.1–6 DNA vaccines have been widely used 
in mouse models, in which they have been shown to success-
fully induce protective immunity against a subsequent challenge 
with tumor cells, as well as in transgenic mouse tumor models, 
which are more likely to reflect the immunological environment 
DNa vaccines are potential tools for the induction of immune responses against both infectious disease and cancer. 
The dermal application of DNa vaccines is of particular interest since the epidermal and dermal layers of the skin are 
characterized by an abundance of antigen-presenting cells (apcs). The aim of our study was to compare tumor protection 
as obtained by two different methods of intradermal DNa delivery (gene gun and jet injector) in a well-established heR2/
neu mouse tumor model. BaLB/c mice were immunized twice with a heR2/neu-coding plasmid by gene gun or jet injector. 
Mice were then subcutaneously challenged with heR2/neu+ syngeneic D2F2/e2 tumor cells. protection against subsequent 
challenges with tumor cells as well as humoral and T-cell immune responses induced by the vaccine were monitored. Gene 
gun immunization was far superior to jet injector both in terms of tumor protection and induction of heR2/neu-specific 
immune responses. after gene gun immunization, 60% of the mice remained tumor-free until day 140 as compared with 
25% after jet injector immunization. Furthermore, gene gun vaccination was able to induce both a strong Th1-polarized 
T-cell response with detectable cytotoxic T-lymphocyte (cTL) activity and a humoral immune response against heR2/neu, 
whereas the jet injector was not. although the disadvantages that were associated with the use of the jet injector in our 
model may be overcome with methodological modifications and/or in larger animals, which exhibit a thicker skin and/or 
subcutaneous muscle tissue, we conclude that gene gun delivery constitutes the method of choice for intradermal DNa 
delivery in preclinical mouse models and possibly also for the clinical development of DNa-based vaccines.
HER2/neu DNA vaccination by intradermal  
gene delivery in a mouse tumor model
Gene gun is superior to jet injector  
in inducing CTL responses and protective immunity
Tam Nguyen-hoai,1,2 Dennis Kobelt,2 Oliver hohn,3 Minh D. Vu,1,2 peter M. schlag,2 Bernd Dörken,1,2 steven Norley,3  
Martin Lipp,2 Wolfgang Walther,2 antonio pezzutto1,2 and Jörg Westermann1,2,*
1Deptartment of hematology, Oncology, and Tumor Immunology charité; University Medicine Berlin; campus Berlin-Buch, campus Benjamin Franklin and campus Virchow-
Klinikum; Berlin, Germany; 2Max Delbrück center for Molecular Medicine; Berlin, Germany; 3Robert Koch Institute; Berlin, Germany
Keywords: CTL response, DNA vaccination, gene gun, HER2/neu, jet injector
of cancer patients.1,2,4,5,7 However, the immunogenicity of DNA 
vaccines in humans and large animals has so far been largely dis-
appointing.8 There is an ongoing debate concerning the main 
reasons for the failure of genetic vaccines in humans, but the most 
important topics are related to dosing, application route, tissue 
distribution, use of adjuvants and differences in Toll-like recep-
tor (TLR) expression patterns between mice and humans.1–5,9–11 
With respect to the application route, the first method described 
was intramuscular injection, which is able to induce signifi-
cant T
H
1-polarized immune responses in mice.12 This method 
was subsequently improved by combining it with electropora-
tion.4,13–15 During the past two decades, several other application 
routes have been investigated, most of which basically rely on 
intramuscular or intradermal gene transfer. In order to avoid a 
direct intradermal injection by syringe and needle, which is dif-
ficult to perform in a reproducible fashion, injection techniques 
such as gene gun particle bombardment, jet injector immuniza-
tion and skin tattooing were introduced.1,2,4,5,16–19 Gene gun deliv-
ery and jet injector are particularly attractive methods from a 
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different intradermal application methods and (2) whether the 
gene gun or the jet injector is the preferable device for the pre-
clinical development of DNA-based vaccines.
Results
Protection after a HER2/neu-targeting DNA vaccination by 
gene gun or jet injector. The efficacy of the two gene delivery 
systems (gene gun and jet injector) was evaluated in BALB/c mice 
that had been immunized on days 1 and 15 with a HER2/neu-
coding plasmid, namely pDNA(HER2/neu). Control groups 
were vaccinated with mock vector (pVax) or gold particles/PBS 
alone. A tumor challenge with D2F2/E2 syngeneic malignant 
cells was performed on day 25. Using the gene gun approach, 
70% of the mice were protected from tumor growth on day 50 
after the tumor challenge, whereas jet injector immunization 
only led to 30% protection (Fig. 1A). With regard to long-term 
protection from tumor growth (day 140), we found that 60% of 
mice remained tumor-free in the gene gun group, whereas only 
25% of the mice treated with jet injector remained devoid of 
tumors (Fig. 1B). In the jet injector group, there was an initial 
low level of tumor protection during the first 50 d after tumor 
challenge. While the difference relative to control groups (pVax- 
and PBS-receiving mice) was statistically significant until day 41, 
this difference waned over time, and the jet injector failed to con-
vey statistically significant protection in the long-term (Fig. 1B).
T-cell immune responses after HER2/neu-targeting DNA 
vaccination by gene gun delivery or jet injector. In order to 
compare HER2/neu-specific T-cell responses after immunization 
by gene gun or jet injector, animals were vaccinated as described 
above. Seven days after the second vaccination, HER2/neu-spe-
cific MHC Class I-restricted immune responses were analyzed by 
ELISpot assays, pentamer staining and cytotoxicity assays. After 
gene gun immunization, a strong T
H
1-polarized HER2/neu-spe-
cific CD8+ T-cell response was detected in ELISpot assays spe-
cific for interferon γ (IFNγ) and interleukin-4 (IL-4), whereas 
jet injector immunization did not induce any T-cell response over 
background levels (Fig. 2). HER2/neu-specific T cells showed a 
clear T
H
1 polarization and the immune response targeted peptides 
from the extracellular domain of HER2/neu (Fig. 2). Results 
obtained with ELISpot assays were confirmed by pentamer stain-
ing, showing a clearly detectable HER2/neu-p63-specific CD8+ 
T-cell population after gene gun, but not jet injector, vaccination. 
Interestingly, HER2/neu-p63-specific T cells could be detected in 
both the spleen and peripheral blood, although the frequency was 
comparatively higher in the latter compartement (Fig. 3).
Since it is generally believed that tumor protection after vacci-
nation strongly correlates with the presence of CTLs, splenocytes 
from vaccinated mice were restimulated in vitro with the HER2/
neu-p63 peptide for 5 d, followed by a standard 51Cr release-based 
cytotoxicity assay, aimed at detecting CTL activity and compar-
ing the induction of CTLs by the two vaccination techniques. 
Target cells were either HER2/neu+ D2F2/E2 tumor cells (with 
D2F2 HER2/neu− tumor cells as a control; Figure 4A and C) 
or HER2/neu− D2F2 tumor cells pulsed with the HER2/neu-
p63 peptide (Fig. 4B and C). This experimental setting was 
clinical point of view: they apply DNA to the skin avoiding high 
injection volumes, which can be painful for patients, particularly 
if repetitive immunizations are being performed. Furthermore, 
they both primarily target the skin, which is characterized by 
a high density of different subpopulations of antigen-presenting 
cells (APCs) including Langerhans cells and dermal dendritic 
cells (DCs).20–25 In addition, jet injection has already been used 
for clinical trials, implying that this device also provides advan-
tages under regulatory aspects.26–30
HER2/neu is an oncogene belonging to the HER family of 
receptor tyrosine kinases and is overexpressed in about 30% of 
patients with breast cancer.31 Being expressed on the cell surface, 
HER2/neu can serve as a target for humoral as well as cellular 
immune responses. T-cell and humoral immune responses tar-
geting HER2/neu have been successfully induced in mice and 
humans.7,32–34 We have previously shown in a BALB/c HER2/neu 
mouse tumor model that the efficacy of an intramuscular HER2/
neu-coding DNA vaccine can be increased by the co-expression 
of chemokines such as the CCR7-ligands CCL19 (also known as 
Epstein-Barr virus-induced molecule 1 ligand chemokine, ELC) 
and CCL21 (also known as secondary lymphoid tissue chemo-
kine, SLC).35,36 In this study, we asked (with respect to a future 
clinical use) whether (1) the efficacy of a HER2/neu-targeting 
DNA vaccine in our experimental system can be improved, in 
terms of protection and anti-HER2/neu immune responses, by 
Figure 1. short- and long-term tumor protection by intradermal DNa 
vaccination using gene gun or jet injector: percentage of tumor-free 
mice after vaccination and tumor challenge. (A and B) Wild-type (WT) 
BaLB/c mice were immunized by gene gun (GG) or jet injector (JI) 
delivery with pDNa(heR2/neu), mock vector (pVax) or gold particles/
pBs on days 1 and 15. On day 25 tumor challenge was performed with 
2 × 105 heR2/neu+ syngeneic D2F2/e2 tumor cells. Tumor growth was 
then monitored thereafter until day 140. n = 10 for each group of mice. 
(A) short-term protection (day 50). (B) Long-term protection (day 140). 
* = statistically significant vs. all other groups (p < 0.05).
humoral and T-cell immune responses against HER2/neu. Of 
note, gene gun DNA delivery—in contrast to jet injection—was 
able to elicit a very strong CTL response, which is believed to be 
crucial for tumor rejection.4,5,7,39,40 However, in order to deter-
mine whether gene gun immunization is able to induce long-
term immunity against HER2/neu in our experimental system, 
an additional tumor challenge at a later time point will have to 
be performed in protected animals. Our results are in line with 
a previous DNA vaccination study by Trimble, et al. based on 
the targeting of a viral antigen in mice.41 These authors report 
that gene gun immunization leads to better tumor protection 
and a higher number of antigen-specific CD8+ T cells as com-
pared with jet injector and intramuscular application. In the 
literature, jet injector systems have been used for gene transfer 
experiments in different tissues such as muscle, skin, mucosa 
and tumor lesions.17,18,26,27,42–47 In addition to many non-immu-
nological strategies, successful DNA vaccination by jet injector 
has been described in animals including mice, rabbits, cattle and 
monkeys, as well as in humans,17,46,48 although these experiments 
were mostly performed with antigens from infectious agents, 
which are presumably more immunogenic. Schramm-Baxter, et 
al. demonstrated that the penetration and dispersion of liquid jets 
selected to determine whether CTL de 
facto recognize tumor cells in a HER2/
neu-specific manner and whether 
HER2/neu-p63-specific T cells (which 
had been detected by pentamer stain-
ing) indeed exert cytolytic activity. 
Our results clearly show that only the 
gene gun immunization protocol is able 
to induce significant levels of HER2/
neu-specific CTLs that are able to lyse 
D2F2/E2 tumor cells in a strictly anti-
gen-specific manner. Indeed, signifi-
cant levels of HER2/neu-directed CTL 
activity over background could not be 
detected after jet injector immunization 
(Fig. 4A). Furthermore, our findings 
indicate that the HER2/neu-p63 pep-
tide is a critical epitope for tumor rejec-
tion in our experimental system.
Humoral immune responses after 
HER2/neu-targeting DNA vaccination 
by gene gun delivery or jet injector. The 
induction of HER2/neu-specific anti-
body responses by the two different vac-
cination methods was evaluated using 
a cytofluorometric assay as described 
above. The analysis was performed on 
serum obtained 7 d after the second 
vaccination. In line with the results 
of HER2/neu-specific T cell analyses, 
significant anti-HER2/neu antibody 
responses (total IgG) were detected only 
upon gene gun immunization, while the 
jet injector delivery was unable to induce 
humoral immune responses over background levels (Fig. 5A). 
Further analysis of the immunoglobulin isotypes showed that 
humoral immune responses predominantly consisted of anti-
HER2/neu antibodies with an IgG1 and—to a lesser extent—
IgG2a and IgG2b isotype (Fig. 5B–D).
Discussion
Even though the intramuscular delivery of DNA vaccines in 
combination with electroporation is efficient in mice and allows 
to reduce injection volumes,37 dermal application systems still 
appear to have potential advantages with regard to clinical use 
in patients. Hence, a comparison of common dermal applica-
tion systems such as the gene gun and the jet injector, as per-
formed in this study, addressed a clinically important question. 
The HER2/neu mouse tumor model that we employed was 
chosen because it is well established, important with respect to 
a potential clinical use in breast cancer patients and suitable for 
a detailed analysis of both MHC-restricted T-cell and humoral 
immune responses.18,36,38 Our study clearly shows that gene gun 
vaccination is superior to jet injector immunization in conveying 
protection against a subsequent tumor challenge and in inducing 
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Figure 2. anti-heR2/neu T-cell immune responses after vaccination. (A and B) splenocytes from 
wild-type (WT) BaLB/c mice intradermally immunized with pDNa(heR2/neu) using gene gun (GG) or 
jet injector (JI) were stimulated with different peptide combinations (derived from the extracellular 
domain or the intracellular domain of heR2/neu, or both). specific T-cell responses were analyzed 
by a interferon γ (IFNγ)-specific (A) or interleukin-4 (IL-4)-specific eLIspot assays. Mice had been 
immunized with DNa on days 1 and 15. eLIspot assays were performed 7 d after the last vaccination. 
For eLIspot assays, splenocytes within the different groups of mice were pooled. ecD, extracellular 
domain; IcD, intracellular domain. * = statistically significant vs. all control groups (p < 0.05).
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and non-immune cells such as keratinocytes seem to be the most 
important drivers of immune responses after gene gun immu-
nization.51 The authors of this study also concluded that cross-
priming (transfected keratinocytes express antigens that are 
taken up by APCs) is much more important than direct priming 
by APCs that have been directly transfected.51 Gene gun particle 
bombardment primarily targets cells in the epidermal and der-
mal layers of the skin,20–22 whereas jet injection delivers a liquid 
formulation of DNA millimeters to centimeters below the skin 
surface.14 This might be particularly disadvantageous in animals 
exhibiting a thin skin layer and/or a lack of substantial subcuta-
neous muscle tissue in the area of vaccination. Previous investiga-
tions show that transgene expression levels in the skin after jet 
injection do not predict the magnitude of immune responses,48 
suggesting that cells in deeper layers and/or cells migrating from 
the skin to regional lymph nodes may play a prominent role in 
determining the efficacy of the vaccine. Furthermore, gene gun 
may lead to a stronger local inflammatory response, owing to 
the huge number of gold particles, causing local injury with a 
scattered distribution pattern. In contrast, jet injector leads to a 
more compact distribution of the DNA-containing liquid and—
depending on the pressure—can reach the subdermal or even the 
muscular tissue, which contain a completely different pattern of 
APCs. In fact, during vaccination, the induction of an appropriate 
in the skin is extremely dependent on the jet power.49 Therefore, 
it seems likely that the immunogenicity of jet injector-delivered 
DNA might be optimized by technical modifications of injection 
depth, pressure and volume (reviewed in ref. 47). However, even 
if this would be the case and would lead to better immunogenic-
ity, our data argue in favor of gene gun delivery as the method of 
choice for intradermal DNA application in mice, since particle 
bombardement to the skin appears to be sufficiently standard-
ized and is usually confined to the upper layers of the skin, where 
APCs can be found in abundance.20–25
A detailed analysis of the mechanism underlying the differ-
ent immunogenicity of gene gun and jet injector delivery in our 
experimental system was far beyond the scope of this study. This 
said, a closer look at the biological mechanism of gene transfer in 
gene gun and jet injector delivery might help explain why gene 
gun is more efficient in inducing HER2/neu-specific immu-
nity. Initially, it was believed that epidermal Langerhans cells 
(LCs) play a major role in the immune response upon intrader-
mal immunization. However, the basic mechsnisms of immune 
responses following intradermal immunization have previously 
been studied in detail. Transfection experiments using cell-
specific promoters demonstrated that LCs are in fact completely 
dispensable for gene gun immunization.50 Conversely, dermal 
DCs, which are located in the subepidermal layer of the skin, 
Figure 3. anti-heR2/neu T-cell immune response after vaccination as detected by heR2/neu-p63-specific pentamer staining. splenocytes from 
wild-type (WT) BaLB/c mice intradermally immunized with pDNa(heR2/neu) using gene gun (GG) or jet injector (JI) were stained with heR2/neu-p63-
specific pentamers. For cytofluoromtetric analyses, splenocytes from mice belonging to the same experimental group were pooled. splenocytes were 
analyzed within a cD3+-restricted gate.
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The American Type Culture Collection cell bank (ATCC) and 
used for cytofluorometric detection of HER2/neu-specific anti-
bodies in animal sera. This cell line was maintained in RPMI 
immunostimulatory microenvironment by 
cytokines decides whether the immunologi-
cal outcome is immunity or tolerance. While 
tolerance results from antigen-presentation in 
a “non-immunogenic” context ( = lack of dan-
ger/inflammatory signals), vaccination may 
elicit strong anti-tumor immune responses, if 
the vaccine and its adjuvant are able to induce 
the maturation/activation of APCs and hence 
the production of T
H
1-polarizing cytokines. 
Furthermore, evidence accumulated during 
the past years points to a complex interplay 
between the innate and the adaptive immune 
system that may determine the final outcome 
of immunization.52–56 In this regard, intra-
dermal immunization by gene gun seems to 
be more immunogenic than jet injection, at 
least in mouse models such as the HER2/neu+ 
tumor model used in our study. Curcio, et 
al. have recently shown that the rejection of 
a HER2/neu+ mouse tumor upon gene gun 
vaccination is indeed dependent on multiple, 
non-redundant innate and adaptive immune 
mechanisms.57 Additionally, it has been dem-
onstrated in a mouse vaccination model that 
gene gun immunization against a viral antigen 
is able to mimic natural infection, in particu-
lar with regard to T-cell responses induced by 
the vaccine.58 Although the results of our study 
are clearly in favor of gene gun delivery, the 
use of the jet injector technology under strictly 
predefined conditions may be more appropri-
ate in larger animals (or humans) exhibiting a 
relatively thick skin layer. Irrespective of this 
issue, our data indicate that gene gun is the 
preferable method for delivering DNA vac-
cines in preclinical mouse models and possibly 
for future clinical development in a situation 
of minimal residual disease after surgery or 
systemic therapy.
Materials and Methods
Cell lines. The mouse mammary tumor 
(MMT) cell line D2F2 is derived from a 
spontaneous mammary tumor that arose in 
a BALB/c background from the hyperplastic 
alveolar nodule (HAN) cell line D2. D2F2/E2 
was transfected with the human HER2/neu 
expression vector pCMV/E2 and the selectable 
plasmid DNA pRSV/neo. The HER2/neu-
expressing cell line D2F2/E2 was maintained 
in DMEM medium containing 800 μg/mL 
G418 (Life Technologies). These cell lines were kindly provided 
by Dr. Thomas Kammertöns (MDC). The human HER2/neu-
overexpressing breast cancer cell line SK-Br3 was purchased from 
Figure 4. cTL assays after vaccination with gene gun or jet injector. (A–C) Wild-type (WT) 
BaLB/c mice were immunized by gene gun (GG) or jet injector immunization (JI) with 
pDNa(heR2/neu), mock vector (pVax) or gold particles/pBs on days 1 and 15. On day 22, sple-
nocytes were restimulated in vitro for 5 d with irradiated BaLB/c 3T3 cells that were pulsed 
with a heR2/neu-p63 peptide. cTL activity was measured in a standard 51cr release assay 
using heR2/neu+ D2F2/e2 tumor cells (A), heR2/neu− D2F2 tumor cells, pulsed with the heR2/
neu-p63 peptide (B), or heR2/neu− D2F2 tumor cells only (negative control) (C). * statistically 
significant vs. all other groups (p < 0.05).
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animal facility (MDC) under standard pathogen-free conditions. 
Experiments have been approved by local authorities (LAGeSo) 
and performed according to the German animal protection law.
Immunization and tumor challenge. Mice were injected twice 
on days 1 and 15, either by DNA-coated gold particle bombard-
ment onto the shaved abdomen using a Helios gene delivery system 
(Biorad) or by jet injector (EMS Medical SA) using DNA con-
taining solution of 1μg DNA/μL PBS. For gene gun vaccination, 
DNA was coated onto 0.8–1.5 μm gold particles following a pro-
tocol developed for the helium-driven gene delivery system from 
Bio-Rad. Two μg DNA per immunization were delivered in two 
shots with a helium discharge pressure of 300–400 psi. Jet injec-
tor immunization was performed by applying five intradermal jet-
injections of 10 μL solution per injection, each of which delivered 
50 μg DNA in total. Technically, this kind of jet injection-based 
DNA delivery should be performed with a DNA concentration 
of 1 μg/μL and allows for a minimum injection volume of 10 
μL. This explains the amount of DNA administered with our jet-
injection device and is in line with previous studies.41 Each experi-
mental group consisted of 5–10 mice. Mice were injected with 
pDNA(HER2/neu) or mock vector (pVax). As further negative 
controls, uncoated gold particles were used for gene gun immuni-
zation and PBS for jet injector vaccination. Ten days after the sec-
ond vaccination, each mouse was challenged with 2 × 105 D2F2/
medium (Lonza) supplemented with 10% FCS (Biochrom), 
2.5 mM 2-mecaptoethanol (Invitrogen), 0.5 mM sodium pyru-
vate (Lonza), 2 mM L-glutamate (Lonza), 0.1 mM MEM 
nonessential amino acids (Lonza) and 100 U/mL penicillin/
streptomycin (Lonza) (complete medium, CM). The expression 
of HER2/neu protein in SK-Br3 cells was confirmed by FACS 
staining using PE-conjugated anti-human HER2/neu antibody 
(BD PharMingen). The percentage of HER2/neu expression in 
the D2F2/E2 cells used in our experiments always exceeded 95%.
HER2/neu-coding plasmid. pVax was purchased from 
Invitrogen. pDNA (HER2/neu) encoding human HER2/
neu was kindly provided by Dr. T. Kammertöns (MDC). The 
HER2/neu plasmid vector pVax/E2A contains the E2A gene 
from pCMV/E2A which was cloned into the expression vector 
pVax. E2A contains mutations at nucleotide positions 2257–2258 
that result in a lysine to alanine exchange at position 753 of the 
amino acid sequence. This alteration leads to elimination of 
tyrosine signaling in the HER2/neu proto-oncogene, an impor-
tant safety feature for potential clinical vaccine development. 
The plasmid was amplified in the Escherichia coli X1-blue strain 
(Agilent Technologies) and purified using the EndoFree Giga-
Prep-Kit (Qiagen) according to the manufacturer’s instructions.
Animals. Female 6–8 weeks old BALB/c mice (H-2kd) 
were purchased from Charles River, and were housed in our 
Figure 5. humoral anti-heR2/neu immune responses after vaccination. (A–D) antibody responses (total IgG and IgG isotypes) against heR2/neu were 
determined by a cytofluorometric assay in wild-type (WT) BaLB/c mice intradermally immunized with pDNa(heR2/neu) using gene gun (GG) or jet in-
jector (JI). Mice had been immunized with DNa on days 1 and 15. cytofluorometric assays were performed 7 d after the last vaccination. (A) anti-heR2/
neu, total IgG. (B) anti-heR2/neu, IgG1. (C) anti-heR2/neu, IgG2a. (D) anti-heR2/neu, IgG2b. * = statistically significant vs. all other groups (p < 0.05).
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ratio of splenocytes:tumor cells used for restimulation was 10:1. 
Peptide-pulsed BALB/c 3T3 cells were maintained for 1 h at 37°C 
in complete medium and PBS at a ratio of 1:1 and subsequently 
irradiated with 100 Gy. D2F2/E2 tumor cells (HER2/neu+) or 
HER2/neu-peptide loaded D2F2 cells were used as target cells in 
a standard 51Cr release assay. Effector cells and target cells were 
incubated at different effector:target ratios (12.5:1 to 200:1) for 
4.5 h at 37°C, after which 50 μL of culture supernatant was 
transferred to lumina plates (Packard Bio Science) and radioac-
tivity measured using a scintillation counter (Top Count). The 
percent specific cytotoxicity was calculated as follows: (% specific 
cytotoxicity = 100 × (experimental release-spontaneous release)/
maximum release-spontaneous release).
Detection of anti-HER2/neu antibodies. Detection of anti-
gen-specific antibodies in the serum by means of flow cytometry 
offers the advantage that it can be performed even if the respec-
tive recombinant protein is not easily available or if its produc-
tion is very cost-intensive. The assay uses target cells that express 
the cognate antigen to bind serum antibodies that are detected 
in a second step by flow cytometry using labeled anti-Ig antibod-
ies.60 Sera were collected from mice and stored at –20°C until use. 
Thawed sera were diluted in PBS to 1:30, 1:60 and 1:120 and 
incubated with 3–5 × 105 SK-BR-3 cells for 30–60 min at 4°C. 
Cells were then washed twice with PBS and resuspended in PBS 
containing 50 μL biotinylated anti mouse IgG, anti mouse IgG1, 
anti mouse IgG2a, anti mouse IgG2b or control antibody diluted 
1:50 (Perkin-Elmer). Cells were incubated for 30–60 min at 4°C, 
washed twice with PBS and resuspended in PBS containing 50 
μL of streptavidin-APC (BD PharMingen) diluted 1:200. Finally, 
cells were incubated for 15–30 min at 4°C, washed with PBS and 
resuspended in FACS-buffer (PBS containing 0.5% BSA, 2 mM 
EDTA, 0.05% NaN
3
) for cytofluorometric analysis. Relative con-
centrations of anti-HER2/neu total serum IgG or IgG isotypes 
were calculated by comparing the mean channel fluorescence 
(MCF) in the different samples. MCF reflects the binding of anti-
HER2/neu antibodies to SK-BR3 cells and is therefore a useful 
measure of humoral anti-HER2/neu immune responses.
Statistical methods. Analysis of variance (ANOVA) of the 
means of three or more groups was performed using the PRISM 
software. The Student’s t-test was used to compare the means of 
two groups. p values < 0.05 were considered statistically significant.
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E2 tumor cells. The appearance and growth of tumors in the mice 
were then monitored 1–2 times per week. Progressively growing 
masses over 1 mm in diameter were regarded as tumors and tumor 
volumes were calculated as 1/6 π d3 (d = diameter).
Preparation of splenocytes. Spleens were aseptically removed 
and single cell suspensions were generated in complete medium. 







). Finally, splenocytes were washed 
twice in RPMI 1640 medium and subsequently used for immu-
nological assays.
ELISpot assays. For ELISpot assays, splenocytes were seeded 
into 4–6 wells (106 splenocytes/well) of interferon γ (IFNγ) or 
interleukin-4 (IL-4) ELISpot plates (ELISpot Kit, PharMingen). 
Peptides were added at a concentration of 1 μg/mL. Plates were 
incubated overnight, developed according to the manufacturer’s 
instructions and analyzed using an ImmunoSpot reader system 
(CTL Europe). Peptide-specific responses were defined as hav-
ing (1) a ratio of specific peptide:control ≥ 2, and (2) an abso-
lute number of spots > 20. Results were expressed as “spots per 
106 splenocytes.” The following HER2/neu peptides were used: 
(1) peptides derived from the extracellular domain (HER2/
neu-ECD): a: HER2p63–71, TYL PTN ASL; b: HER2p342–
350, CYG LGM EHL; c: HER2p369–377, KIF GSL AFL; d: 
HER2p440–448, AYS LTL QGL; (2) peptides derived from 
the intracellular domain (HER2:neu-ICD), a: HER2p773–
782, VMA GVG SPY V; b: HER2p780–788, PYV SRL LG; 
c: HER2–2p883–899 KVP IKW MAL ESI LRR RF; d: 
HER2p907–915, SYG VTV WEL. H-2kd restriction and poten-
tial immunogenicity in mice have previously been shown for 
most of these peptides.59 Using the BIMAS epitope prediction 
algorithm (www.bimas.cet.nih.gov), most peptides were found to 
be high affinity binders for H-2kd. Only peptides 1c, 2a and 2c 
were predicted to have a low affinity for H-2kd. All peptides were 
purchased from Wita GmbH and had a purity of ≥ 95%.
Pentamer staining. To detect peripheral or splenic HER2/
neu-p63-specific CD8+ T cells, lymphocytes isolated from the 
blood of mice on day 6 or from spleens on day 7 after the second 
vaccination were stained with a PE-labeled pentamer that recog-
nizes the HER2/neu-p63 epitope (ProImmune Ltd.) using the 
manufacturer’s protocol. Lymphocytes were then further stained 
with a mix of the antibodies containing CD3-FITC, CD8-APC 
(PharMingen) and CD19 PerCP-Cy5.5 (Biolegend). Stained 
cells were detected using a BD FACS-Canto cytofluorometer and 
analysis was performed with the FlowJo software.
Cytotoxicity assays. Splenocytes were restimulated in vitro 
for 5 d in complete medium in the presence of 10 U/mL IL-2 
(Roche) and syngeneic BALB/c 3T3 cells pulsed with 10 μg/mL 
HER2/neu-p63 peptide (WITA GmbH) as described above. The 
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